Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors
← catalyst calendarSponsored by Gilead Sciences (industry) · GILD — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
227actual
Sites
65
Countries
Australia, Belgium, Canada +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-10-15 | actual | When the study began enrolling |
| Primary completion | 2025-01-15 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2019-05-28 | actual | When this record first appeared on the registry |
| Results posted | 2026-01-30 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-04-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Solid Tumor
Intervention
- Drug: Sacituzumab Govitecan-hziy — also filed as IMMU-132, GS-0132
Primary outcome
what the primary-completion date above is the date OFObjective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator's Assessment
measured Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-12-17 · 5.8 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-04-14 · 1.5 MB · SAP_001.pdf
Publications
- PMID 39083724 — cited as background
- PMID 39665770 — cited as background
- PMID 39755168 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed